<unk>  is being trialled as an experimental vaccine against respiratory syncytial virus, RSV, in the general infant population. The vaccine intends to replace existing RSV treatment palivizumab, and a single dose is enough for an infants first entire RSV season, Sanofi and AstraZeneca claim.
Nirsevimab
Atoltivimab
Regdanvimab
Odesivimab
Sotrovimab
Obiltoxaximab
Maftivimab
Bebtelovimab